Oral Session 1-8D Malignant Lymphoma: Clinical studies

[OS1-8D-6] Post-marketing survey of brentuximab vedotin in patients with relapsed/refractory HL and sALCL

Tomoko Yanai¹, Koji Izutsu^2,3, Michinori Ogura⁴, Kensei Tobinai², Kiyohiko Hatake⁵, Shigeru Sakamoto¹, Yasuhiro Katsura⁶, Masanori Nishimura⁶, Mikiko Hashimoto¹ (1.Japan Medical Affairs, Takeda Pharmaceutical Co. Ltd., Tokyo, Japan, 2.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 3.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 4.Department of Hematology/Oncology, Kasugai Municipal Hospital, Kasugai, Japan, 5.Department of Hematology and Oncology, Cancer Institute Hospital, Tokyo, Japan, 6.Pharmacovigilance, Takeda Pharmaceutical Co. Ltd., Osaka, Japan)